Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer

Melissa A. Getter, Tri M. Bui-Nguyen, Lisa M. Rogers, Sundaram Ramakrishnan

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objectives: Tumor infiltrating macrophages play an important role in tumor progression. Macrophage chemoattractant protein-1 (MCP-1) is one of the major chemokines responsible for inducing macrophage migration. Our objective was to investigate chemotherapy-induced modulation of MCP-1 in ovarian cancer by investigating macrophage infiltration, tumor vascularity, and MCP-1 expression after chemotherapy exposure. Methods: MA-148 ovarian cancer cells were treated with paclitaxel (43 pg/mL) and carboplatin (5μg/mL) alone or in combination. Reverse transcription-polymerase chain reaction determined MCP-1 transcript levels and enzyme-linked immunosorbent assay evaluated MCP-1 protein production at multiple time points. The effect of kinase inhibitors on MCP-1 expression was investigated. In vivo MCP-1 production was examined in tumor-bearing mice and immunohistochemistry with fluorescein isothiocyanate conjugated anti-mouse F4/80 antibody, phycoerythrin-anti-CD31, and terminal deoxynucleotide transferase dUTP nick-end labeling assay were performed. Results: Macrophage chemoattractant protein-1 transcript levels were up-regulated in MA-148 after treatment with paclitaxel and carboplatin individually and in combination. The greatest elevation was seen with combination therapy: 2.5-fold increase in the MCP-1 protein levels from baseline (P = 0.011) with the mitogen-activated protein kinase and janus kinases/signal transducers and activators of transcription pathways appearing to be involved in the regulation of MCP-1 production. In vivo mouse studies confirmed increased MCP-1 production after chemotherapy; however, there was no significant difference in macrophage, apoptosis, or vessel density. Conclusions: Macrophage chemoattractant protein-1 is up-regulated in ovarian cancer after chemotherapy in vitro and in vivo. Whether MCP-1 production is increased because of a stress-induced response or a scavenger response promoting macrophage infiltration remains unknown. Chemotherapy induction of MCP-1 in ovarian cancer suggests this chemokine plays an important role in the immune response occurring after chemotherapy exposure.

Original languageEnglish (US)
Pages (from-to)918-925
Number of pages8
JournalInternational Journal of Gynecological Cancer
Volume20
Issue number6
DOIs
StatePublished - Aug 1 2010
Externally publishedYes

Fingerprint

Chemotactic Factors
Ovarian Neoplasms
Macrophages
Drug Therapy
Proteins
Carboplatin
Paclitaxel
Chemokines
Neoplasms
Phycoerythrin
Janus Kinases
Induction Chemotherapy
Mitogen-Activated Protein Kinase Kinases

Keywords

  • Macrophage
  • MCP-1
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer. / Getter, Melissa A.; Bui-Nguyen, Tri M.; Rogers, Lisa M.; Ramakrishnan, Sundaram.

In: International Journal of Gynecological Cancer, Vol. 20, No. 6, 01.08.2010, p. 918-925.

Research output: Contribution to journalArticle

Getter, Melissa A. ; Bui-Nguyen, Tri M. ; Rogers, Lisa M. ; Ramakrishnan, Sundaram. / Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer. In: International Journal of Gynecological Cancer. 2010 ; Vol. 20, No. 6. pp. 918-925.
@article{67a02f7c32bf463d9001d450b4f3461c,
title = "Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer",
abstract = "Objectives: Tumor infiltrating macrophages play an important role in tumor progression. Macrophage chemoattractant protein-1 (MCP-1) is one of the major chemokines responsible for inducing macrophage migration. Our objective was to investigate chemotherapy-induced modulation of MCP-1 in ovarian cancer by investigating macrophage infiltration, tumor vascularity, and MCP-1 expression after chemotherapy exposure. Methods: MA-148 ovarian cancer cells were treated with paclitaxel (43 pg/mL) and carboplatin (5μg/mL) alone or in combination. Reverse transcription-polymerase chain reaction determined MCP-1 transcript levels and enzyme-linked immunosorbent assay evaluated MCP-1 protein production at multiple time points. The effect of kinase inhibitors on MCP-1 expression was investigated. In vivo MCP-1 production was examined in tumor-bearing mice and immunohistochemistry with fluorescein isothiocyanate conjugated anti-mouse F4/80 antibody, phycoerythrin-anti-CD31, and terminal deoxynucleotide transferase dUTP nick-end labeling assay were performed. Results: Macrophage chemoattractant protein-1 transcript levels were up-regulated in MA-148 after treatment with paclitaxel and carboplatin individually and in combination. The greatest elevation was seen with combination therapy: 2.5-fold increase in the MCP-1 protein levels from baseline (P = 0.011) with the mitogen-activated protein kinase and janus kinases/signal transducers and activators of transcription pathways appearing to be involved in the regulation of MCP-1 production. In vivo mouse studies confirmed increased MCP-1 production after chemotherapy; however, there was no significant difference in macrophage, apoptosis, or vessel density. Conclusions: Macrophage chemoattractant protein-1 is up-regulated in ovarian cancer after chemotherapy in vitro and in vivo. Whether MCP-1 production is increased because of a stress-induced response or a scavenger response promoting macrophage infiltration remains unknown. Chemotherapy induction of MCP-1 in ovarian cancer suggests this chemokine plays an important role in the immune response occurring after chemotherapy exposure.",
keywords = "Macrophage, MCP-1, Ovarian cancer",
author = "Getter, {Melissa A.} and Bui-Nguyen, {Tri M.} and Rogers, {Lisa M.} and Sundaram Ramakrishnan",
year = "2010",
month = "8",
day = "1",
doi = "10.1111/IGC.0b013e3181e5c442",
language = "English (US)",
volume = "20",
pages = "918--925",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer

AU - Getter, Melissa A.

AU - Bui-Nguyen, Tri M.

AU - Rogers, Lisa M.

AU - Ramakrishnan, Sundaram

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Objectives: Tumor infiltrating macrophages play an important role in tumor progression. Macrophage chemoattractant protein-1 (MCP-1) is one of the major chemokines responsible for inducing macrophage migration. Our objective was to investigate chemotherapy-induced modulation of MCP-1 in ovarian cancer by investigating macrophage infiltration, tumor vascularity, and MCP-1 expression after chemotherapy exposure. Methods: MA-148 ovarian cancer cells were treated with paclitaxel (43 pg/mL) and carboplatin (5μg/mL) alone or in combination. Reverse transcription-polymerase chain reaction determined MCP-1 transcript levels and enzyme-linked immunosorbent assay evaluated MCP-1 protein production at multiple time points. The effect of kinase inhibitors on MCP-1 expression was investigated. In vivo MCP-1 production was examined in tumor-bearing mice and immunohistochemistry with fluorescein isothiocyanate conjugated anti-mouse F4/80 antibody, phycoerythrin-anti-CD31, and terminal deoxynucleotide transferase dUTP nick-end labeling assay were performed. Results: Macrophage chemoattractant protein-1 transcript levels were up-regulated in MA-148 after treatment with paclitaxel and carboplatin individually and in combination. The greatest elevation was seen with combination therapy: 2.5-fold increase in the MCP-1 protein levels from baseline (P = 0.011) with the mitogen-activated protein kinase and janus kinases/signal transducers and activators of transcription pathways appearing to be involved in the regulation of MCP-1 production. In vivo mouse studies confirmed increased MCP-1 production after chemotherapy; however, there was no significant difference in macrophage, apoptosis, or vessel density. Conclusions: Macrophage chemoattractant protein-1 is up-regulated in ovarian cancer after chemotherapy in vitro and in vivo. Whether MCP-1 production is increased because of a stress-induced response or a scavenger response promoting macrophage infiltration remains unknown. Chemotherapy induction of MCP-1 in ovarian cancer suggests this chemokine plays an important role in the immune response occurring after chemotherapy exposure.

AB - Objectives: Tumor infiltrating macrophages play an important role in tumor progression. Macrophage chemoattractant protein-1 (MCP-1) is one of the major chemokines responsible for inducing macrophage migration. Our objective was to investigate chemotherapy-induced modulation of MCP-1 in ovarian cancer by investigating macrophage infiltration, tumor vascularity, and MCP-1 expression after chemotherapy exposure. Methods: MA-148 ovarian cancer cells were treated with paclitaxel (43 pg/mL) and carboplatin (5μg/mL) alone or in combination. Reverse transcription-polymerase chain reaction determined MCP-1 transcript levels and enzyme-linked immunosorbent assay evaluated MCP-1 protein production at multiple time points. The effect of kinase inhibitors on MCP-1 expression was investigated. In vivo MCP-1 production was examined in tumor-bearing mice and immunohistochemistry with fluorescein isothiocyanate conjugated anti-mouse F4/80 antibody, phycoerythrin-anti-CD31, and terminal deoxynucleotide transferase dUTP nick-end labeling assay were performed. Results: Macrophage chemoattractant protein-1 transcript levels were up-regulated in MA-148 after treatment with paclitaxel and carboplatin individually and in combination. The greatest elevation was seen with combination therapy: 2.5-fold increase in the MCP-1 protein levels from baseline (P = 0.011) with the mitogen-activated protein kinase and janus kinases/signal transducers and activators of transcription pathways appearing to be involved in the regulation of MCP-1 production. In vivo mouse studies confirmed increased MCP-1 production after chemotherapy; however, there was no significant difference in macrophage, apoptosis, or vessel density. Conclusions: Macrophage chemoattractant protein-1 is up-regulated in ovarian cancer after chemotherapy in vitro and in vivo. Whether MCP-1 production is increased because of a stress-induced response or a scavenger response promoting macrophage infiltration remains unknown. Chemotherapy induction of MCP-1 in ovarian cancer suggests this chemokine plays an important role in the immune response occurring after chemotherapy exposure.

KW - Macrophage

KW - MCP-1

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=77956842693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956842693&partnerID=8YFLogxK

U2 - 10.1111/IGC.0b013e3181e5c442

DO - 10.1111/IGC.0b013e3181e5c442

M3 - Article

VL - 20

SP - 918

EP - 925

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 6

ER -